Krilogy Financial LLC Purchases New Position in Repligen Corporation $RGEN

Key Points

• Krilogy Financial LLC has invested approximately $2.51 million in Repligen Corporation, acquiring 20,201 shares of the biotechnology company's stock.
• Following a lackluster earnings report, Repligen's stock has been given mixed ratings from analysts, with price targets ranging from $135.00 to $205.00.
• 97.64% of Repligen's stock is owned by hedge funds and institutional investors, highlighting the company's strong institutional interest.

Krilogy Financial LLC acquired a new stake in shares of Repligen Corporation (NASDAQ:RGEN - Free Report) in the second quarter, according to the company in its most recent filing with the SEC. The firm acquired 20,201 shares of the biotechnology company's stock, valued at approximately $2,513,000.

Other institutional investors have also modified their holdings of the company. Alliance Wealth Advisors LLC UT lifted its holdings in shares of Repligen by 2.5% in the 1st quarter. Alliance Wealth Advisors LLC UT now owns 3,675 shares of the biotechnology company's stock worth $468,000 after buying an additional 89 shares during the period. State of Michigan Retirement System lifted its holdings in Repligen by 0.8% during the first quarter. State of Michigan Retirement System now owns 12,453 shares of the biotechnology company's stock worth $1,585,000 after buying an additional 100 shares during the period. Louisiana State Employees Retirement System increased its holdings in shares of Repligen by 0.7% in the 1st quarter. Louisiana State Employees Retirement System now owns 14,600 shares of the biotechnology company's stock valued at $1,858,000 after acquiring an additional 100 shares during the period. State of Wyoming raised its position in shares of Repligen by 5.2% in the 1st quarter. State of Wyoming now owns 2,338 shares of the biotechnology company's stock worth $297,000 after acquiring an additional 115 shares in the last quarter. Finally, Signaturefd LLC lifted its stake in shares of Repligen by 65.3% during the 1st quarter. Signaturefd LLC now owns 324 shares of the biotechnology company's stock worth $41,000 after purchasing an additional 128 shares during the last quarter. 97.64% of the stock is owned by hedge funds and other institutional investors.

Repligen Stock Performance

Shares of NASDAQ:RGEN traded down $2.08 during midday trading on Friday, reaching $122.30. The company's stock had a trading volume of 1,103,283 shares, compared to its average volume of 738,209. The firm has a market capitalization of $6.88 billion, a PE ratio of -489.18, a P/E/G ratio of 2.29 and a beta of 1.07. The stock has a fifty day moving average of $119.78 and a 200 day moving average of $126.72. Repligen Corporation has a twelve month low of $102.96 and a twelve month high of $182.52. The company has a quick ratio of 7.32, a current ratio of 8.59 and a debt-to-equity ratio of 0.26.

Repligen (NASDAQ:RGEN - Get Free Report) last posted its quarterly earnings results on Tuesday, July 29th. The biotechnology company reported $0.37 EPS for the quarter, missing the consensus estimate of $0.40 by ($0.03). The business had revenue of $182.37 million during the quarter, compared to analysts' expectations of $174.62 million. Repligen had a negative net margin of 2.05% and a positive return on equity of 4.61%. Repligen's revenue for the quarter was up 14.8% compared to the same quarter last year. During the same period in the previous year, the company posted $0.40 earnings per share. Repligen has set its FY 2025 guidance at 1.650-1.720 EPS. On average, equities analysts expect that Repligen Corporation will post 1.72 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on RGEN shares. HC Wainwright reiterated a "buy" rating and issued a $180.00 target price on shares of Repligen in a research note on Wednesday, September 3rd. Wells Fargo & Company cut their price objective on shares of Repligen from $180.00 to $175.00 and set an "overweight" rating on the stock in a research report on Wednesday, July 30th. Stephens raised shares of Repligen to an "overweight" rating and set a $160.00 target price for the company in a research report on Tuesday, July 22nd. Jefferies Financial Group lowered their target price on shares of Repligen from $145.00 to $135.00 and set a "hold" rating for the company in a research note on Friday, September 12th. Finally, Wall Street Zen lowered Repligen from a "buy" rating to a "hold" rating in a report on Sunday, June 29th. Eight research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company's stock. According to data from MarketBeat.com, Repligen has an average rating of "Moderate Buy" and an average price target of $166.67.

Insiders Place Their Bets

In related news, Director Martin D. Madaus purchased 1,800 shares of the firm's stock in a transaction on Friday, August 8th. The stock was bought at an average cost of $112.13 per share, with a total value of $201,834.00. Following the completion of the acquisition, the director owned 1,800 shares of the company's stock, valued at $201,834. The trade was a ∞ increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Corporate insiders own 1.20% of the company's stock.

Repligen Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.